Brian C. Stephenson Sells 8,500 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CFO Brian C. Stephenson sold 8,500 shares of BridgeBio Pharma stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $33.19, for a total value of $282,115.00. Following the completion of the transaction, the chief financial officer now owns 102,464 shares in the company, valued at approximately $3,400,780.16. This represents a 7.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

BridgeBio Pharma Trading Down 5.4 %

BridgeBio Pharma stock traded down $1.89 during trading hours on Monday, hitting $33.01. 3,282,866 shares of the stock traded hands, compared to its average volume of 3,176,007. The firm's 50-day moving average price is $32.79 and its two-hundred day moving average price is $28.40. The company has a market cap of $6.28 billion, a PE ratio of -11.58 and a beta of 1.07. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $39.47.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($1.09) by ($0.22). The firm had revenue of $5.88 million during the quarter, compared to analysts' expectations of $4.04 million. On average, sell-side analysts expect that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

Remove Ads

Institutional Trading of BridgeBio Pharma

A number of hedge funds have recently made changes to their positions in BBIO. Farallon Capital Management LLC boosted its position in shares of BridgeBio Pharma by 140.1% in the 4th quarter. Farallon Capital Management LLC now owns 4,195,000 shares of the company's stock worth $115,111,000 after purchasing an additional 2,448,000 shares in the last quarter. Woodline Partners LP boosted its position in shares of BridgeBio Pharma by 132.9% in the 4th quarter. Woodline Partners LP now owns 2,211,521 shares of the company's stock worth $60,684,000 after purchasing an additional 1,261,772 shares in the last quarter. Norges Bank bought a new stake in shares of BridgeBio Pharma in the 4th quarter worth approximately $29,237,000. Alyeska Investment Group L.P. bought a new stake in shares of BridgeBio Pharma in the 4th quarter worth approximately $25,805,000. Finally, Capital Research Global Investors boosted its position in shares of BridgeBio Pharma by 34.9% in the 4th quarter. Capital Research Global Investors now owns 3,526,747 shares of the company's stock worth $96,774,000 after purchasing an additional 912,439 shares in the last quarter. 99.85% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on BBIO. Cantor Fitzgerald reiterated an "overweight" rating and issued a $95.00 price objective on shares of BridgeBio Pharma in a report on Friday, February 21st. Citigroup boosted their price target on BridgeBio Pharma from $45.00 to $49.00 and gave the company a "buy" rating in a report on Friday, February 21st. HC Wainwright restated a "buy" rating and set a $49.00 price target on shares of BridgeBio Pharma in a report on Thursday, February 13th. Bank of America boosted their price target on BridgeBio Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a report on Monday, November 25th. Finally, Evercore ISI boosted their price target on BridgeBio Pharma from $45.00 to $50.00 and gave the company an "outperform" rating in a report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat.com, BridgeBio Pharma has a consensus rating of "Moderate Buy" and an average price target of $51.67.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.